Upstream Bio Inc. (UPB) is approaching a critical inflection point, with a key clinical data readout anticipated in the near term.
The company's lead drug candidate is Verekitug, being developed as a potential treatment for severe respiratory diseases. It targets the thymic stromal lymphopoietin (TSLP) receptor, a key driver in the inflammatory pathways underlying conditions such as asthma, COPD, and chronic rhinosinusitis with nasal polyps.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com